Program
HRS-8427
A development code. Also written as “HRS-8427 injection plus furosemide”.
In Jiangsu HengRui Medicine's pipeline, Cefiderocol derivatives
. Its studies are mostly in Pneumonia, Bacterial · Pyelonephritis · Gram-Negative Bacterial Infections, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 60 open or running | phase 3since Aug 22, 2024 | Aug 22, 2024 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-8427
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 22, 2024First study: phase 3 study in Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)First studyNCT06569056 · 579 enrolled · China
- Feb 19, 2025Phase 2 study in Hospital-acquired Bacterial Pneumonia (HABP)NCT06841731 · 120 enrolled · China
- Jun 24, 20253 phase 1 studiesNCT07049107, NCT07049562, NCT07073157
- Jul 8, 2025Phase 1 study in Gram-Negative Bacterial InfectionsNCT07070375 · 33 enrolled · China
- Sep 30, 2026Primary completion moved from 2026-02 to 2026-09-22Date moved laterphase 2 · +7 months · NCT06841731
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cefiderocol derivatives”the company's pipeline, read by Claude · source
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07070375Gram-Negative Bacterial Infections · China | 1 | Completed | Aug 23, 2023 | 33 |
| NCT07073157Health Volunteer · China | 1 | Completed | Aug 15, 2025 | 24 |
| NCT07049562Healthy Cninese Adult Male · China | 1 | Completed | Jun 18, 2025 | 6 |
| NCT07049107Health Volunteer · China | 1 | Completed | Jul 21, 2025 | 14 |
| NCT06841731Hospital-acquired Bacterial Pneumonia (HABP) · China | 2 | Completed | Sep 22, 2026 | 120 |
| NCT06569056Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) · China | 3 | Completed | Sep 1, 2026 | 579 |
How it is read
Names in the registry
- “HRS-8427”, 5 entries
- “HRS-8427 injection plus furosemide”, 1 entry
Codes read as this program: HRS8427.
Conditions, from the studies’ own filings
- Pneumonia, Bacterial, 1 study
- Pyelonephritis, 1 study
- Gram-Negative Bacterial Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.